Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Top 10 Best-Selling Drugs Of Q1 2023: Keytruda Topples Humira

COVID-19 Products And Humira Decline As Keytruda Continues Ascent

Executive Summary

A review of the top-selling drugs of the first quarter of 2023 demonstrate the declining turnover from products to treat or prevent COVID-19, as well as a precipitative drop by Humira. Merck & Co’s PD-1 inhibitor Keytruda grew strongly, and Novo Nordisk’s injectable diabetes drug Ozempic burst into the top 10 ranks.

Related Content


Related Companies

Latest Headlines
See All



Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts